Automation, Rapid Diagnostics, and Rising Sepsis Burden Drive Global Blood Culture Test Market to US$14 Billion by 2032
Industry Experts, Inc. has unveiled its latest market research publication, "Blood Culture Test - A Global Market Overview," estimating that global revenues will rise from US$7 billion in 2025 to US$14 billion by 2032, registering a CAGR of 10.5% during 2025-2032. Growth is powered by rising cases of bloodstream infections and sepsis, increased antimicrobial resistance, expanding surgical and ICU admissions, and rapid adoption of automated and molecular diagnostic technologies that improve speed, accuracy, and clinical outcomes. Rising sepsis-related mortality, an aging and immunocompromised population, and increasing hospital-acquired infections have strengthened clinical emphasis on early pathogen detection and targeted therapy. Advancements in continuous-monitoring culture systems, PCR-based assays, and MALDI-TOF MS proteomics are transforming diagnostic workflows, reducing turnaround times, and supporting antibiotic stewardship. Hospitals are implementing automated blood culture platforms to comply with global sepsis management guidelines, while emerging markets are accelerating investments in lab modernization, infection control initiatives, and rapid diagnostics adoption. Although high instrument costs and operational constraints in developing regions remain challenges, continued R&D investment, AI-assisted interpretation tools, and regulatory approvals for faster and more sensitive systems are driving sustained market expansion.
Industry Experts, Inc. has unveiled its latest market research publication, "Blood Culture Test - A Global Market Overview," estimating that global revenues will rise from US$7 billion in 2025 to US$14 billion by 2032, registering a CAGR of 10.5% during 2025-2032. Growth is powered by rising cases of bloodstream infections and sepsis, increased antimicrobial resistance, expanding surgical and ICU admissions, and rapid adoption of automated and molecular diagnostic technologies that improve speed, accuracy, and clinical outcomes.
Rising sepsis-related mortality, an aging and immunocompromised population, and increasing hospital-acquired infections have strengthened clinical emphasis on early pathogen detection and targeted therapy. Advancements in continuous-monitoring culture systems, PCR-based assays, and MALDI-TOF MS proteomics are transforming diagnostic workflows, reducing turnaround times, and supporting antibiotic stewardship. Hospitals are implementing automated blood culture platforms to comply with global sepsis management guidelines, while emerging markets are accelerating investments in lab modernization, infection control initiatives, and rapid diagnostics adoption. Although high instrument costs and operational constraints in developing regions remain challenges, continued R&D investment, AI-assisted interpretation tools, and regulatory approvals for faster and more sensitive systems are driving sustained market expansion.
Transform your PDFs into Flipbooks and boost your revenue!
Leverage SEO-optimized Flipbooks, powerful backlinks, and multimedia content to professionally showcase your products and significantly increase your reach.
Automation, Rapid Diagnostics, and Rising Sepsis
Burden Drive Global Blood Culture Test Market to US$14
Billion by 2032
Wednesday Nov 26, 2025
Industry Experts, Inc. has unveiled its latest market research publication, "Blood Culture Test
- A Global Market Overview," estimating that global revenues will rise from US$7 billion in
2025 to US$14 billion by 2032, registering a CAGR of 10.5% during 2025-2032. Growth is
powered by rising cases of bloodstream infections and sepsis, increased antimicrobial
resistance, expanding surgical and ICU admissions, and rapid adoption of automated and
molecular diagnostic technologies that improve speed, accuracy, and clinical outcomes.
Rising sepsis-related mortality, an aging and immunocompromised population, and increasing
hospital-acquired infections have strengthened clinical emphasis on early pathogen detection
and targeted therapy. Advancements in continuous-monitoring culture systems, PCR-based
assays, and MALDI-TOF MS proteomics are transforming diagnostic workflows, reducing
turnaround times, and supporting antibiotic stewardship. Hospitals are implementing
automated blood culture platforms to comply with global sepsis management guidelines, while
emerging markets are accelerating investments in lab modernization, infection control
initiatives, and rapid diagnostics adoption. Although high instrument costs and operational
constraints in developing regions remain challenges, continued R&D investment, AI-assisted
© Industry Experts, Inc. All Rights Reserved
interpretation tools, and regulatory approvals for faster and more sensitive systems are
driving sustained market expansion.
North America dominates the global blood culture test market with a 39.9% share in 2025,
supported by advanced healthcare infrastructure, strong R&D spending, high sepsis
prevalence, and robust adoption of automated systems from leading companies such as BD,
bioMerieux, and Thermo Fisher. Favorable reimbursement, stringent infection control
regulations, and federally funded antimicrobial resistance programs further strengthen
regional leadership. In contrast, Asia-Pacific is projected to grow the fastest at an 11.5%
CAGR through 2032, fueled by rising infectious disease burden, modernization of diagnostic
laboratories, expanded automation across China and India, supportive government programs,
and increasing awareness of early sepsis detection.
By product, Consumables lead the market with a 57% share in 2025, driven by essential
single-use culture bottles, media, and reagents required for every test and reinforced by
updated sepsis protocols. Instruments are set to expand the fastest at an 11.3% CAGR,
propelled by rising automation and demand for high-throughput, real-time detection platforms.
By method, Conventional/Manual Methods retain a 59% share, particularly in cost-sensitive
regions, while Automated Methods grow the fastest at 11.2% CAGR due to improved
accuracy, reduced contamination risk, and integration with molecular tools. By technology,
Culture-based testing dominates with a 64% share, maintaining its status as the gold
standard for viable pathogen detection and antimicrobial susceptibility testing. Molecular
technology grows the fastest at 11.6% CAGR, driven by rapid pathogen and resistance gene
identification. By application, Bacteremia leads with over 70% share, while Fungemia
expands the fastest at more than 11% CAGR. By end user, Hospital Laboratories hold a 55%
share, with Reference Laboratories growing the fastest at 11.8% CAGR, supported by
outsourcing trends and high-volume, complex testing capabilities.
The report segments the global Blood Culture Test market by Product (Consumables,
Instruments, Software & Services), Method (Conventional/Manual Methods, Automated
Methods), Technology (Culture-based, Molecular, Proteomics-based), Application
(Bacteremia, Fungemia, Mycobacterial Detection), and End User (Hospital Laboratories,
Reference Laboratories, Academic & Research, Other End Users). Geographic coverage
spans North America, Europe, Asia-Pacific, South America, and Rest of World, with profiles of
11+ companies, including Abbott, BD, bioMerieux, Bruker, Danaher, DiaSorin, Roche,
Siemens Healthineers, Terumo, and Thermo Fisher Scientific.
For sample pages or purchase options, contact +1-320-497-3787 or visit Blood Culture Test
Market.
© Industry Experts, Inc. All Rights Reserved
About Industry Experts, Inc.
Industry Experts, Inc. ranks among the leading global market research providers. The
company's off-the-shelf and customized business intelligence reports offer strategic insights
and valuable guidance to corporate strategists, analysts, researchers, and startups seeking
unbiased current and future market data. For more information, contact +1-320-497-3787 or
visit https://industry-experts.com.
© Industry Experts, Inc. All Rights Reserved
Change language